KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) EBT: 2009-2024

Historic EBT for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to -$63.1 million.

  • Pacira BioSciences' EBT rose 106.86% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.8 million, marking a year-over-year increase of 176.17%. This contributed to the annual value of -$63.1 million for FY2024, which is 202.28% down from last year.
  • Latest data reveals that Pacira BioSciences reported EBT of -$63.1 million as of FY2024, which was down 202.28% from $61.7 million recorded in FY2023.
  • Over the past 5 years, Pacira BioSciences' EBT peaked at $61.7 million during FY2023, and registered a low of -$63.1 million during FY2024.
  • Over the past 3 years, Pacira BioSciences' median EBT value was $13.3 million (recorded in 2022), while the average stood at $4.0 million.
  • Per our database at Business Quant, Pacira BioSciences' EBT skyrocketed by 363.85% in 2023 and then tumbled by 202.28% in 2024.
  • Yearly analysis of 5 years shows Pacira BioSciences' EBT stood at $20.1 million in 2020, then soared by 180.77% to $56.4 million in 2021, then tumbled by 76.42% to $13.3 million in 2022, then spiked by 363.85% to $61.7 million in 2023, then tumbled by 202.28% to -$63.1 million in 2024.